[FPRX] Five Prime Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 1.25 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 51.31 Change: 0.98 (1.95%)

chart FPRX

Refresh chart

Strongest Trends Summary For FPRX

FPRX is in the long-term down -54% in 1 year and down -83% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company?s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC; Glaxo Group Limited; GSK-HGS; Pfizer Inc.; and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding28.2 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -13.93% Sales Growth - Q/Q-7.71% P/E
P/E To EPS Growth P/S62.54 P/BV8.07 Price/Cash Per Share5.75
Price/Free Cash Flow91.69 ROA-17.73% ROE-25.73% ROI
Current Ratio11.41 Quick Ratio Long Term Debt/Equity Debt Ratio0.12
Gross Margin Operating Margin-200.57% Net Profit Margin-199.36% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities79.58 M Cash From Investing Activities-69.81 M Cash From Operating Activities-10.55 M Gross Profit
Net Profit-11.04 M Operating Profit-11.14 M Total Assets224.57 M Total Current Assets220.33 M
Total Current Liabilities19.31 M Total Debt Total Liabilities69.8 M Total Revenue4.29 M
Technical Data
High 52 week21.26 Low 52 week8.12 Last close11.97 Last change1.7%
RSI60.2 Average true range0.45 Beta1.38 Volume214.71 K
Simple moving average 20 days4.23% Simple moving average 50 days15.57% Simple moving average 200 days-12.58%
Performance Data
Performance Week3.37% Performance Month15.65% Performance Quart5.28% Performance Half-14.07%
Performance Year-32.33% Performance Year-to-date28.71% Volatility daily3.47% Volatility weekly7.75%
Volatility monthly15.89% Volatility yearly55.05% Relative Volume286.4% Average Volume367.39 K
New High New Low

News

2019-03-19 09:28:01 | Will Five Prime Therapeutics Continue to Surge Higher?

2019-03-19 08:29:45 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-03-12 10:27:29 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-03-11 06:00:00 | Five Prime Has 5 Drugs in its Pipeline

2019-03-06 08:03:09 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-03-05 18:05:00 | Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

2019-03-05 08:04:58 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-02-27 03:02:16 | Edited Transcript of FPRX earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-26 21:47:48 | Five Prime Therapeutics Inc FPRX Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:05:00 | Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-25 10:30:11 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-02-20 20:05:00 | Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150

2019-02-15 08:02:35 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-02-08 08:04:13 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-02-07 16:05:00 | Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26

2019-02-04 17:05:00 | Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum

2019-01-30 23:45:02 | Why are deep-pocketed biotechs cutting hundreds of jobs?

2019-01-28 09:37:02 | MacroGenics Up on Lifting of Partial Hold on Cancer Candidate

2019-01-24 03:13:08 | Five Prime Therapeutics, Inc. FPRX Shares March Higher, Can It Continue?

2019-01-18 08:03:43 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-01-17 14:05:00 | Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology ASCO Gastrointestinal GI Cancers Symposium

2019-01-17 08:03:57 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-01-16 07:40:00 | Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indications

2019-01-15 17:08:33 | Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line

2019-01-15 16:05:00 | Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities

2019-01-15 08:03:42 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-01-14 18:41:00 | Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium

2019-01-13 15:50:01 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

2019-01-08 08:05:49 | See what the IHS Markit Score report has to say about Re/Max Holdings Inc.

2018-12-20 08:06:12 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-12-19 18:50:33 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-12-18 08:06:44 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-12-12 16:05:00 | Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-04 08:06:23 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-11-29 16:05:00 | Five Prime Therapeutics Announces Changes to its Board of Directors

2018-11-27 07:15:00 | 3 Top Biotech Stocks to Buy Right Now

2018-11-24 08:06:48 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-11-22 08:04:33 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-11-20 16:05:00 | Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference

2018-11-15 08:04:30 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-11-14 16:05:00 | Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein

2018-11-13 08:04:36 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-11-12 10:21:15 | Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more

2018-11-09 08:40:00 | New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group — Consolidated Revenues, Company Growth, and Expectations for 20

2018-11-09 08:06:30 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2018-11-07 05:15:41 | Edited Transcript of FPRX earnings conference call or presentation 6-Nov-18 9:30pm GMT

2018-11-06 18:15:11 | Five Prime Therapeutics FPRX Reports Q3 Loss, Misses Revenue Estimates

2018-11-06 17:09:32 | Five Prime Therapeutics: 3Q Earnings Snapshot

2018-11-06 16:05:00 | Five Prime Therapeutics Announces Third Quarter 2018 Financial Results

2018-11-05 10:36:00 | Five Prime Therapeutics Announces David V. Smith Will Join as Chief Financial Officer